Kenneth L McClain1, Jennifer Picarsic2, Rikhia Chakraborty1, Daniel Zinn1, Howard Lin1, Harshal Abhyankar1, Brooks Scull1, Albert Shih1, Karen Phaik Har Lim1,3, Olive Eckstein1, Joseph Lubega1, Tricia L Peters1,4, Walter Olea1, Thomas Burke1, Nabil Ahmed1, M John Hicks1,4, Brandon Tran5, Jeremy Jones5, Robert Dauser6, Michael Jeng7, Robert Baiocchi8, Deborah Schiff9, Stanton Goldman10, Kenneth M Heym11, Harry Wilson12, Benjamin Carcamo13, Ashish Kumar14, Carlos Rodriguez-Galindo15, Nicholas S Whipple15, Patrick Campbell15, Geoffrey Murdoch16, Julia Kofler16, Simon Heales17, Marian Malone18, Randy Woltjer19, Joseph F Quinn19, Paul Orchard20, Michael C Kruer21, Ronald Jaffe22, Markus G Manz23, Sergio A Lira24, D Williams Parsons1,25, Miriam Merad26, Tsz-Kwong Man1, Carl E Allen1. 1. Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. 2. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas. 4. Department of Pathology, Baylor College of Medicine, Houston, Texas. 5. Department of Radiology, Baylor College of Medicine, Houston, Texas. 6. Department of Neurosurgery, Baylor College of Medicine, Houston, Texas. 7. Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California. 8. Department of Internal Medicine, The Ohio State University, Columbus, Ohio. 9. Department of Pediatrics, University of California-San Diego, La Jolla, California. 10. Medical City Children's Hospital, Dallas Texas and Texas Oncology, Pennsylvania. 11. Department of Pediatrics, Cook Children's Medical Center, Fort Worth, Texas. 12. Department of Pathology, Texas Tech University Health Sciences Center El Paso, El Paso, Texas. 13. Department of Pediatrics, Texas Tech University Health Sciences Center El Paso, El Paso, Texas. 14. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 15. St. Jude Children's Research Hospital, Memphis, Tennessee. 16. Department of Pathology, Division of Neuropathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 17. Chemical Pathology, Great Ormond Street Hospital for Children, London, UK. 18. Laboratory Medicine, Great Ormond Street Hospital for Children, London, UK. 19. Layton Aging and Alzheimer's Disease Center, Oregon Health and Science University, Portland, Oregon. 20. Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota. 21. Barrow Neurological Institute, Phoenix Children's Hospital; Child Health, Neurology & Genetics, University of Arizona College of Medicine, Phoenix, Arizona. 22. Department of Pathology, Magee-Women's Hospital of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 23. Division of Hematology, University of Zurich, University Hospital Zurich, Zurich, Switzerland. 24. Immunology Institute, Icahn School of Medicine, New York, New York. 25. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. 26. Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine, New York, New York.
Abstract
BACKGROUND: Central nervous system Langerhans cell histiocytosis (CNS-LCH) brain involvement may include mass lesions and/or a neurodegenerative disease (LCH-ND) of unknown etiology. The goal of this study was to define the mechanisms of pathogenesis that drive CNS-LCH. METHODS: Cerebrospinal fluid (CSF) biomarkers including CSF proteins and extracellular BRAFV600E DNA were analyzed in CSF from patients with CNS-LCH lesions compared with patients with brain tumors and other neurodegenerative conditions. Additionally, the presence of BRAFV600E was tested in peripheral mononuclear blood cells (PBMCs) as well as brain biopsies from LCH-ND patients, and the response to BRAF-V600E inhibitor was evaluated in 4 patients with progressive disease. RESULTS: Osteopontin was the only consistently elevated CSF protein in patients with CNS-LCH compared with patients with other brain pathologies. BRAFV600E DNA was detected in CSF of only 2/20 (10%) cases, both with LCH-ND and active lesions outside the CNS. However, BRAFV600E+ PBMCs were detected with significantly higher frequency at all stages of therapy in LCH patients who developed LCH-ND. Brain biopsies of patients with LCH-ND demonstrated diffuse perivascular infiltration by BRAFV600E+ cells with monocyte phenotype (CD14+ CD33+ CD163+ P2RY12- ) and associated osteopontin expression. Three of 4 patients with LCH-ND treated with BRAF-V600E inhibitor experienced significant clinical and radiologic improvement. CONCLUSION: In LCH-ND patients, BRAFV600E+ cells in PBMCs and infiltrating myeloid/monocytic cells in the brain is consistent with LCH-ND as an active demyelinating process arising from a mutated hematopoietic precursor from which LCH lesion CD207+ cells are also derived. Therapy directed against myeloid precursors with activated MAPK signaling may be effective for LCH-ND. Cancer 2018;124:2607-20.
BACKGROUND: Central nervous system Langerhans cell histiocytosis (CNS-LCH) brain involvement may include mass lesions and/or a neurodegenerative disease (LCH-ND) of unknown etiology. The goal of this study was to define the mechanisms of pathogenesis that drive CNS-LCH. METHODS: Cerebrospinal fluid (CSF) biomarkers including CSF proteins and extracellular BRAFV600E DNA were analyzed in CSF from patients with CNS-LCH lesions compared with patients with brain tumors and other neurodegenerative conditions. Additionally, the presence of BRAFV600E was tested in peripheral mononuclear blood cells (PBMCs) as well as brain biopsies from LCH-ND patients, and the response to BRAF-V600E inhibitor was evaluated in 4 patients with progressive disease. RESULTS: Osteopontin was the only consistently elevated CSF protein in patients with CNS-LCH compared with patients with other brain pathologies. BRAFV600E DNA was detected in CSF of only 2/20 (10%) cases, both with LCH-ND and active lesions outside the CNS. However, BRAFV600E+ PBMCs were detected with significantly higher frequency at all stages of therapy in LCH patients who developed LCH-ND. Brain biopsies of patients with LCH-ND demonstrated diffuse perivascular infiltration by BRAFV600E+ cells with monocyte phenotype (CD14+ CD33+ CD163+ P2RY12- ) and associated osteopontin expression. Three of 4 patients with LCH-ND treated with BRAF-V600E inhibitor experienced significant clinical and radiologic improvement. CONCLUSION: In LCH-ND patients, BRAFV600E+ cells in PBMCs and infiltrating myeloid/monocytic cells in the brain is consistent with LCH-ND as an active demyelinating process arising from a mutated hematopoietic precursor from which LCH lesion CD207+ cells are also derived. Therapy directed against myeloid precursors with activated MAPK signaling may be effective for LCH-ND. Cancer 2018;124:2607-20.
Authors: Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins Journal: Blood Date: 2010-06-02 Impact factor: 22.113
Authors: Marie-Luise Berres; Karen Phaik Har Lim; Tricia Peters; Jeremy Price; Hitoshi Takizawa; Hélène Salmon; Juliana Idoyaga; Albert Ruzo; Philip J Lupo; M John Hicks; Albert Shih; Stephen J Simko; Harshal Abhyankar; Rikhia Chakraborty; Marylene Leboeuf; Monique Beltrão; Sérgio A Lira; Kenneth M Heym; Venetia Bigley; Matthew Collin; Markus G Manz; Kenneth McClain; Miriam Merad; Carl E Allen Journal: J Exp Med Date: 2014-03-17 Impact factor: 14.307
Authors: Felice D'Arco; Livja Mertiri; Pim de Graaf; Bert De Foer; Katarina S Popovič; Maria I Argyropoulou; Kshitij Mankad; Hervé J Brisse; Amy Juliano; Mariasavina Severino; Sofie Van Cauter; Mai-Lan Ho; Caroline D Robson; Ata Siddiqui; Steve Connor; Sotirios Bisdas Journal: Neuroradiology Date: 2022-04-23 Impact factor: 2.804
Authors: Nallammai Muthiah; Kamil W Nowicki; Jennifer L Picarsic; Michael P D'Angelo; Daniel F Marker; Edward G Andrews; Edward A Monaco; Ajay Niranjan Journal: J Neurosurg Case Lessons Date: 2021-05-10
Authors: Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen Journal: Nat Rev Dis Primers Date: 2021-10-07 Impact factor: 65.038
Authors: C Matthias Wilk; Rikhia Chakraborty; Steven T Chen; Carl E Allen; Miriam Merad; Camille Bigenwald; Jessica Le Berichel; Alexandra Tabachnikova; Rebecca Mancusi; Harshal Abhyankar; Maria Casanova-Acebes; Ilaria Laface; Guray Akturk; Jenielle Jobson; Zoi Karoulia; Jerome C Martin; John Grout; Anahita Rafiei; Howard Lin; Markus G Manz; Alessia Baccarini; Poulikos I Poulikakos; Brian D Brown; Sacha Gnjatic; Amaia Lujambio; Kenneth L McClain; Jennifer Picarsic Journal: Nat Med Date: 2021-05-06 Impact factor: 87.241